World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day

Ingelheim, Germany, Wednesday, 27/09/2023 - 11:00

Sir Peter J. Ratcliffe, winner of the 2019 Nobel Prize in Physiology or Medicine, is among the many distinguished guests at Boehringer Ingelheim’s second Transforming Science Day, where he will talk about the importance of partnerships in medical research to bring transformative innovation to patients.

Scientists, research partners and other life science innovation leaders will gather at the Francis Crick Institute in London on Oct. 2 for Boehringer Ingelheim’s second Transforming Science Day
Boehringer Ingelheim will show its approach to innovation and research partnership as well as profile its blossoming pipeline. Further progress in partnered medical research programs and a range of new partnerships will be announced
Members of Boehringer Ingelheim’s Talent Acquisition team will be available to discuss career opportunities across its global research sites

Why it matters

Boehringer Ingelheim cultivates first-in-class science, fueled by a passion for identifying and addressing the areas of greatest unmet patient need. The event will provide the opportunity to experience the company’s collaborative culture that is driving its pipeline and striving to deliver breakthrough therapies that transform the lives of patients.

“We are excited to host Boehringer Ingelheim’s Transforming Science Day as it exemplifies the Crick’s philosophy. Science is rooted in collaboration and the Crick is all about partnerships and collaboration. Embracing translational science drives advances.” - Sir Peter J. Ratcliffe, Clinical Research Director at the Francis Crick Institute.

"Breakthrough discoveries are driven by visionary thinkers and great teams who share the passion to bring breakthrough therapies to address unmet patient needs. When we come together, we can create things that are greater than each of us individually.” - Michel Pairet, Member of the Board of Managing Directors at Boehringer Ingelheim with responsibility for the Innovation Unit.

Register to attend the science day

To attend in person: Boehringer Ingelheim’s Transforming Science Day: Europe
To join online: Transforming Science Day: Europe | LinkedIn

Learn more about our clinical pipeline

View our pipeline

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com  

Boehringer Ingelheim’s Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.